API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Historical End-of-Day API Real-time Prices API Financial Events & News API Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 152 articles Forum Github 14 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. F /
  3. AGW0.F

ALGERNON PHARMACEUT. A (AGW0 F) stock market data APIs

€0.0245 -0.02(-50.6%) as of October 31, 2024
Price chart is built with Anychart

Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, pancreatic and small cell lung cancer, and acute lung injury in Canada and Australia. The company's pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries. The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.

ALGERNON PHARMACEUT. A Financial Data Overview

0.0395
0.0245
-
0.043
0.0245
0.0155-0.0935
1 086 K
27 301 K
0
-0.2
-0.398
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'AGW0',
Type: 'Common Stock',
Name: 'ALGERNON PHARMACEUT. A',
Exchange: 'F',
CurrencyCode: 'EUR',
CurrencyName: 'Euro',
CurrencySymbol: '€',
CountryName: 'Germany',
CountryISO: 'DE',
OpenFigi: NULL,
ISIN: 'CA01559R4008',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'August',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

ALGERNON PHARMACEUT. A Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -2 842 369
  • Earnings Per Share -0.02
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get ALGERNON PHARMACEUT. A Earnings via APIs

  • Latest Release 2023-01-30
  • EPS/Forecast -0.16

Get ALGERNON PHARMACEUT. A End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get ALGERNON PHARMACEUT. A latest news via APIs

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD

VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical sta...
  • ALGERNON PHARMACEUTICALS
  • CANADIAN STOCK EXCHANGE:AGN.CN
  • CKD AND NASH
  • PATENT
  • PATENTS
  • REPIRINAST

Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

VANCOUVER, British Columbia, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical s...
  • ALGERNON PHARMACEUTICALS
  • CANADIAN STOCK EXCHANGE:AGN.CN
  • CHRONIC COUGH
  • IFENPRODIL
  • LOI
  • MERGERS AND ACQUISITIONS
  • PHASE 2B
News API is available at any package from $19.99 See full price
Get sample of News API
Do you have any questions?
support@eodhistoricaldata.com